Shilpa Pharma, Inc. v. Novartis Pharmaceuticals Corporation
Opinion
Case: 24-1181 Document: 39 Page: 1 Filed: 07/10/2025
NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit
______________________ SHILPA PHARMA, INC., Appellant v.
NOVARTIS PHARMACEUTICALS CORPORATION,
Appellee ______________________
2024-1181 ______________________
Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2022- 00886.
______________________ JUDGMENT ______________________
MARK BOLAND, Sughrue Mion, PLLC, Washington, DC, argued for appellant. Also represented by MICHAEL R. DZWONCZYK, RAJA SALIBA.
WILLIAM M. JAY, Goodwin Procter LLP, Washington, DC, argued for appellee. Also represented by ELIZABETH A. KIERNAN, Gibson, Dunn & Crutcher LLP, Dallas, TX; JANE M. LOVE, ROBERT TRENCHARD, New York, NY.
______________________
Case: 24-1181 Document: 39 Page: 2 Filed: 07/10/2025 THIS CAUSE having been heard and considered, it is ORDERED and ADJUDGED:
PER CURIAM (MOORE, Chief Judge, STOLL, Circuit Judge, and BUMB, Chief District Judge1).
AFFIRMED. See Fed. Cir. R. 36.
ENTERED BY ORDER OF THE COURT July 10, 2025
Date
Case-law data current through September 30, 2026. Source: CourtListener bulk data.